Article thumbnail

Oscillatory Photodynamic Therapy for Choroidal Neovascularization and Central Serous Retinopathy; a Pilot Study

By Gholam A Peyman, Michael Tsipursky, Nariman Nassiri and Mandi Conway
Topics: Original Article
Publisher: Ophthalmic Research Center
OAI identifier: oai:pubmedcentral.nih.gov:3306098
Provided by: PubMed Central

Suggested articles

Citations

  1. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: The VIA study.
  2. Canadian Retinal Trials Group. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial.
  3. Changes in aqueous vascular endothelial growth factor and pigment epitheliumderived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
  4. Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy.
  5. Choroidal neovascularization following photodynamic therapy in a patient with chronic central serous chorioretinopathy.
  6. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.
  7. Chronic central serous chorioretinopathy: photodynamic therapy.
  8. (2011). Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the Oscillatory PDT;
  9. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study.
  10. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation.
  11. (2003). Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol
  12. (1990). Control of subretinal fluid: experimental and clinical studies. Eye (Lond)
  13. Doserelated structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.
  14. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
  15. (2006). Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model. Graefes Arch Clin Exp Ophthalmol
  16. Efficacy of combined photodynamic therapy and subTenon’s capsule injection of triamcinolone acetonide for age-related macular degeneration.
  17. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy.
  18. (1996). Flotte TJ, Gragoudas ES. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol
  19. (2011). Food and Drug Administration Center for Drug Evaluation and Research. Approval letter, Application 21-119. http://www.accessdata.fda. gov/drugsatfda_docs/nda/2002/21-119%20S-004_ Visudyne_Approv.PDF. Accessed
  20. Half dose verteporfin PDT for central serous chorioretinopathy.
  21. Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy.
  22. Histopathological changes following photodynamic therapy in human eyes.
  23. (2004). Individualisierung der Behandlungsparameter der PDT. Klin Monatsbl Augenheilkund
  24. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288-
  25. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.
  26. Intravitrreal bevacizumab injection for central serous chorioretinopathy.
  27. Low-fluence photodynamic therapy in longstanding chronic central serous chorioretinopathy with foveal and gravitational atrophy.
  28. Low-fluence-rate photodynamic therapy to treat subfoveal choroidal neovascularization in pathological myopia. A study of efficacy and safety. Graefes Arch Clin Exp Ophthalmol
  29. (2007). Management of neovascular age-related macular degeneration. Prog Retin Eye Res
  30. Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin.
  31. Ocular changes after photodynamic therapy.
  32. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy.
  33. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
  34. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization.
  35. Photodynamic therapy for choroidal neovascularization: a review.
  36. Photodynamic therapy in chronic central serous chorioretinopathy.
  37. (1995). Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin.
  38. Problems with and pitfalls of photodynamic therapy.
  39. Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study.
  40. Regression of peripapillary choroidal neovascularization after oscillatory transpupillary thermotherapy and anti-VEGF pharmacotherapy.
  41. (2011). Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752-763. Oscillatory PDT;
  42. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
  43. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females.
  44. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.
  45. The pathophysiology of cigarette smoking and agerelated macular degeneration.
  46. The structural basis of the blood-ocular barriers.
  47. Transient serous retinal detachment in classic and occult choroidal neovascularization after photodynamic therapy.
  48. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial.
  49. (2009). Triple therapy for age-related macular degeneration. Retina
  50. Triple therapy for choroidal neovascularization due to agerelated macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.
  51. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone.
  52. (1994). Vascular targeting in photodynamic occlusion of subretinal vessels.
  53. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.